Array Biopharma (ARRY) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.30 -3.23%
EPS Growth %: -70.0%
Financial Fact:
Weighted average shares outstanding - diluted (in shares): 145.1M
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: -70.0%
Financial Fact:
Weighted average shares outstanding - diluted (in shares): 145.1M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $44.52 million versus the consensus estimate of $30.99 million.
COLUMBUS / BRAF-mutant melanoma New Drug Application (NDA) expected to file in June or July
NEMO / NRAS-mutant melanoma target action date under the Prescription Drug User Fee Act (PDUFA) on June 30, 2017
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- Tractor Supply (TSCO) Tops Q3 EPS by 3c; offers guidance
- Quest Diagnostics (DGX) Tops Q3 EPS by 13c; raises guidance
Create E-mail Alert Related Categories
Earnings, FDA, GuidanceRelated Entities
Earnings, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
